Saturday | 7 September 2024 | Reg No- 06
বাংলা সংস্করণ
Advance Search
   
Saturday | 7 September 2024
LATEST: Constable arrested over shooting student to death in Gazipur   15 nursing students fall ill during symbolic poison-drinking protest   All industries reopen in Gazipur amid tight security   12 workers injured in Ctg shipyard explosion   Prof Yunus visits victims at Neuroscience Hospital   Madrasa students will be deployed to provide security during Durga Puja   Committee by Sunday to turn Ganabhaban into museum: Asif   

A watershed in Hepatitis-B treatment with ‘Nashvac’

Published : Sunday, 4 August, 2024 at 12:00 AM  Count : 964
The announcement of 'Nashvac,' a groundbreaking vaccine developed by Bangladeshi medical scientists Dr. Sheikh Md Fazle Akbar and Dr. Mamun Al Mahtab Swapnil, marks a significant milestone in the fight against Hepatitis-B. 

Hepatitis-B, a viral infection that attacks the liver and can cause both acute and chronic diseases, has long been a global health challenge. While vaccines for Hepatitis-C have been developed, a fully effective vaccine to treat Hepatitis-B has remained elusive-until now. The announcement that 'Nashvac' will be available by the end of this year is nothing short of revolutionary for both the medical community and the countless individuals affected by Hepatitis-B.

A workshop hosted by National Press Club and attended by notable figures such as MP, and leading scientists from Bangabandhu Sheikh Mujib Medical University, highlighted urgency and significance of this advancement. According to Dr. Sheikh Fazle Akbar, between 3 to 8 million people in Bangladesh are affected by Hepatitis, with approximately 500,000 facing severe health challenges. The lack of awareness and insufficient screening exacerbate the problem, making the introduction of 'Nashvac' a critical step forward.

Additionally, Dr. Mamun Al Mahtab Swapnil, Head of the Interventional Hepatology Division, emphasized the importance of completing the three-dose vaccine regimen to achieve immunity and prevent serious complications. The vaccine has shown no side effects and promises to offer protection by developing antibodies, making it a safe and essential tool in combating Hepatitis-B.

The role of Beacon Pharmaceutical PLC in producing and distributing 'Nashvac' is crucial. Their commitment to bringing this vaccine to market reflects a broader dedication in improving public health and addressing pressing medical needs. As vaccine becomes available, it is imperative for government, healthcare providers, and community organizations to collaborate on comprehensive awareness campaigns. Educating public about the importance of screening, vaccination, and treatment is vital to curbing the spread of Hepatitis-B and ensuring that individuals at risk receive timely and effective care.

However, the development of 'Nashvac' not only represents a triumph in medical science but also underscores the growing capacity of Bangladeshi scientists and pharmaceutical companies to contribute to global health solutions. This achievement should be celebrated as a beacon of progress and a reminder of the power of innovation and perseverance in the face of formidable challenges.

Last but not least, let us acknowledge significant strides made in Hepatitis-B treatment and support the efforts to increase awareness and access to this life-saving vaccine. 'Nashvac' offers a new path to healing for millions, and its introduction heralds a brighter future for those battling Hepatitis-B.



LATEST NEWS
MOST READ
Also read
Editor : Iqbal Sobhan Chowdhury
Published by the Editor on behalf of the Observer Ltd. from Globe Printers, 24/A, New Eskaton Road, Ramna, Dhaka.
Editorial, News and Commercial Offices : Aziz Bhaban (2nd floor), 93, Motijheel C/A, Dhaka-1000.
Phone: PABX- 41053001-06; Online: 41053014; Advertisement: 41053012.
E-mail: info©dailyobserverbd.com, news©dailyobserverbd.com, advertisement©dailyobserverbd.com, For Online Edition: mailobserverbd©gmail.com
🔝